• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4640428)   Today's Articles (1841)   Subscriber (50384)
For: Liu Q, Luo X, Zhou Z, Peng L, Yi L, Wan X, Tan C, Zeng X. PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC: A Cost-Effectiveness Analysis in China. Front Oncol 2021;11:745493. [PMID: 34966668 PMCID: PMC8710478 DOI: 10.3389/fonc.2021.745493] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2021] [Accepted: 11/22/2021] [Indexed: 11/13/2022]  Open
Number Cited by Other Article(s)
1
Zhang X, Fan X, Zhang J, Jiang F, Wu Y, Yang B, Li X, Liu D. Cost-effectiveness analysis of the tislelizumab versus docetaxel for advanced or metastatic non-small-cell lung cancer in China. Front Public Health 2024;12:1425734. [PMID: 39091529 PMCID: PMC11291238 DOI: 10.3389/fpubh.2024.1425734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2024] [Accepted: 07/08/2024] [Indexed: 08/04/2024]  Open
2
Qi H, Zhang W, Chen B, Zhan Q, Wang T, Shi H, Liu Y, Wang Y, Zhong M, Shi X, Shen F, Li Q. Clinical outcomes and medical resource utilization of toripalimab combination therapy versus bevacizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer. Curr Med Res Opin 2024;40:441-453. [PMID: 38193524 DOI: 10.1080/03007995.2024.2303122] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/10/2023] [Accepted: 01/04/2024] [Indexed: 01/10/2024]
3
Chen Z, Hu T, Zhou J, Gu X, Chen S, Qi Q, Wang L. Overview of tumor immunotherapy based on approved drugs. Life Sci 2024;340:122419. [PMID: 38242494 DOI: 10.1016/j.lfs.2024.122419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Revised: 12/25/2023] [Accepted: 01/07/2024] [Indexed: 01/21/2024]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA